Literature DB >> 6308993

Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors.

R L DeLaPaz, N J Patronas, R A Brooks, B H Smith, P L Kornblith, H Milam, G Di Chiro.   

Abstract

Positron emission tomography (PET) scanning with [18F]-2-fluoro-2-deoxy-D-glucose (FDG) was used to study 59 patients with astrocytomas and three patients with other cerebral mass lesions. Suppression of gray-matter glucose utilization ranging from 8% to 64% (mean, 30%) was seen in 92% of cases. Three categories of suppression were apparent, with the greatest degrees of suppression occurring in edematous gray matter adjacent to mass lesions. Lesser degrees of suppression were noted in nonedematous structures (normal attenuation on computed tomographic scan) adjacent to the lesion. Significant suppression was also present in gray matter spatially remote from but functionally linked to the site of the lesion. This approach may become a useful tool for improved understanding of the clinical presentation of certain pathologic entities and for evaluation of disease progression and response to treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6308993      PMCID: PMC8335004     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  14 in total

Review 1.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Semin Cancer Biol       Date:  2008-12-03       Impact factor: 15.707

2.  Diagnostic manifestations of total hemispheric glucose metabolism ratio in neuronal network diaschisis: diagnostic implications in Alzheimer's disease and mild cognitive impairment.

Authors:  Eivind A Segtnan; Alireza Majdi; Caius Constantinescu; Peter Grupe; Oke Gerke; Heini Í Dali; Olaf Emil Strøm; Jorun Holm; Abass Alavi; Saeed Sadigh-Eteghad; Lene Wermuth; Malene G Hildebrandt; Albert Gjedde; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-12       Impact factor: 9.236

Review 3.  The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Biochim Biophys Acta       Date:  2010-04-08

4.  Blood flow and oxygen utilisation in the contralateral cerebral cortex of patients with untreated intracranial tumours as studied by positron emission tomography, with observations on the effect of decompressive surgery.

Authors:  R P Beaney; D J Brooks; K L Leenders; D G Thomas; T Jones; K E Halnan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-04       Impact factor: 10.154

Review 5.  Metabolic targeting of malignant tumors: small-molecule inhibitors of bioenergetic flux.

Authors:  Saroj P Mathupala
Journal:  Recent Pat Anticancer Drug Discov       Date:  2011-01       Impact factor: 4.169

6.  Intraoperative infrared imaging of brain tumors.

Authors:  Alexander M Gorbach; John D Heiss; Leonid Kopylev; Edward H Oldfield
Journal:  J Neurosurg       Date:  2004-12       Impact factor: 5.115

7.  Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas.

Authors:  R G Henry; D B Vigneron; N J Fischbein; P E Grant; M R Day; S M Noworolski; J M Star-Lack; L L Wald; W P Dillon; S M Chang; S J Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

Review 8.  Brain tumors.

Authors:  K L Black; J C Mazziotta; D P Becker
Journal:  West J Med       Date:  1991-02

Review 9.  PET in clinical oncology.

Authors:  R A Hawkins; M E Phelps
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

10.  Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomas.

Authors:  K Mineura; T Yasuda; M Kowada; T Ogawa; F Shishido; K Uemura
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.